Colivelin

About Colivelin

Colivelin is a hybrid peptide: activity-dependent neurotrophic factor fused to the N-terminus of AGA-(C8R)HNG17, a potent humanin derivative. Its headline property is extraordinary in-vitro potency — it fully suppressed neuronal death caused by familial Alzheimer's genes and amyloid-beta at 100 femtomolar, working through two pathways (CaMKIV via the ADNF component and STAT3 via the humanin component). In mouse models it improved memory and reduced amyloid deposition in PDAPP and APP/PS1 mice and prolonged survival in an ALS model. All of that is animal and cell-culture work, and much of it used intrahippocampal or intranasal administration rather than systemic dosing. The femtomolar potency figure is also worth holding alongside vial sizes: a compound active at 100 femtomolar in a dish is being sold in 50mg and 100mg vials, quantities with no relationship to any studied dose. It is closely related to Humanin, already in this catalog.

Key Benefits

• Active at 100 femtomolar against Alzheimer's-relevant insults in vitro
• Improved memory and reduced amyloid deposition in two mouse models
• Prolonged survival in an ALS mouse model
• Dual mechanism — CaMKIV and STAT3 pathways

Category Ratings

How to Take

Common Side Effects

• Unknown — no human safety data exists
• Injection site reactions
• Systemic effects entirely uncharacterised

Legal & Regulatory Status

Research use only. Not FDA-approved and never tested in humans. All efficacy data is from cell culture and mouse models, largely via direct brain or intranasal administration.

Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.

Research & Sources

• Development of colivelin, a femtomolar-acting humanin derivative — original characterisation (PMID 16267233)
• Protective effects of colivelin against Alzheimer's disease in a PDAPP mouse model (PMID 26964005)
• Colivelin ameliorates cognitive and synaptic impairments in APP/PS1 transgenic mice (PMID 28731445)
• Colivelin prolongs survival of an ALS model mouse (PMID 16564029)

Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.